Tau-PET pathology correlates with cognition and disease severity in Progressive Supranuclear Palsy
Poster No:
2443
Submission Type:
Abstract Submission
Authors:
Roxane Dilcher1, Charles Malpas2, Terence O'Brien1, Lucy Vivash1
Institutions:
1Dept. of Neuroscience, Monash University, Melbourne, VIC, 2University of Melbourne, Melbourne, VIC
First Author:
Co-Author(s):
Introduction:
For primary tau pathologies, such as Progressive Supranuclear Palsy (PSP), there are currently no specific biomarkers, limiting disease diagnosis and the development of treatments. The recently introduced positron emission tomography (PET) radiotracer 18F-PI-2620 has the potential to detect abnormal tau protein in PSP. This study investigates the correlation between tau-PET and clinical markers in PSP.
Methods:
In this preliminary, cross-sectional analysis, 16 patients with clinically diagnosed probable PSP (Richardson's Syndrome) underwent T1-weighted MRI and 0-60 min dynamic 18F-PI-2620 PET scanning. Standardized uptake value ratios (SUVr) were generated for regions of interest (globus pallidus, frontal, and occipital lobe). Clinical assessments included the Digit Span Memory task, Hayling, Stroop, Trail Making Test, National Institutes of Health (NIH) toolbox subtasks, the Behaviour Rating Inventory of Executive Function (BRIEF-A, 'Never'-scores), and the PSP Rating Scale (PSP-RS). Voxel-wise and region-based multiple regression analyses tested the associations between SUVr and clinical markers. Data was pre-processed and analysed with FSL, SPM, and R.
Results:
Tau uptake in the basal ganglia was negatively associated with the Digit Span Reverse task or the BRIEF-A (voxel-wise, p<0.01). Region-based analyses showed that tau uptake in the basal ganglia was significantly predicted by impairments in the Digit Span Forward and Reverse task (p<0.01), working memory subtask of the NIH toolbox (p<0.05), and the BRIEF-A (p<0.05). No positive associations were found in the frontal or occipital regions. There were significant clinical scales by region interactions, with the basal ganglia showing stronger negative associations in the Digit Span tasks, working memory subtask, oral reading recognition subtask, and BRIEF-A, compared to the frontal and the occipital lobe (p<0.05).
·Voxel-wise results
·ROI-based results
Conclusions:
Associations between executive dysfunctions, disease severity and tau uptake in the basal ganglia suggest suitability of the 18F-PI-2620 tracer as an in-vivo tau biomarker for the diagnosis and tracking of disease progression in PSP. New biomarkers are essential for the advancement of future clinical trials.
Disorders of the Nervous System:
Neurodegenerative/ Late Life (eg. Parkinson’s, Alzheimer’s) 2
Higher Cognitive Functions:
Executive Function, Cognitive Control and Decision Making
Novel Imaging Acquisition Methods:
PET 1
Keywords:
Basal Ganglia
Cognition
Movement Disorder
Positron Emission Tomography (PET)
1|2Indicates the priority used for review
Provide references using author date format
Kroth, H. (2019), ‘Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's disease and other tauopathies.’ European journal of nuclear medicine and molecular imaging. vol. 46, no. 10, pp. 2178-2189